Latest Thesis
Acumen Pharmaceuticals (ABOS): the Alzheimer readout racing a cash clock
Acumen's sabirnetug story is dominated by one late-2026 ALTITUDE-AD readout, a going-concern warning, and a cash runway that may not reach commercial proof.
Financials and workspace tools are for paid members.
Paid login unlocks company financials, filing timeline, peer comparison, scorecard, and discussion. Valuation remains admin-only while we finalize market-data licensing.
Recent Reports
Compact report index for this company.
ReportTypeUpdatedReadActions
Acumen Pharmaceuticals (ABOS): the Alzheimer readout racing a cash clockAcumen's sabirnetug story is dominated by one late-2026 ALTITUDE-AD readout, a going-concern warning, and a cash runway that may not reach commercial proof.NASDAQMay 13, 2026Research reportReadSlides